Sequenom Center for Molecular Medicine® (Sequenom CMM) is using revolutionary new technology to develop assays that have the potential to advance prenatal care for mothers.
A new noninvasive technology from Sequenom, called SEQureDx™, enables the detection and analysis of circulating fetal nucleic acid (RNA or DNA) in a pregnant woman. Rather than harvesting placental tissue cells (as is required for chorionic villus sampling), or entering the uterus to sample the amniotic fluid surrounding the baby (as is done with amniocentesis), circulating fetal nucleic acid can be extracted safely and comfortably from the blood of the mother.
By applying our breakthrough technology to frequently encountered diagnostics challenges in pregnancy and reproduction, Sequenom CMM believes it can provide advanced tools to assist women, their families and their healthcare providers in achieving the best pregnancy outcomes.
Follow the links to the left for more information.